A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

NCT01911221 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of the Meningococcal Disease

Interventions

BIOLOGICAL: rMenB+OMV NZ

Sponsor

Novartis Vaccines

Collaborators

[object Object]